Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)[1].

AstraZeneca has entered into an agreement to acquire Guangdong BeiKang Pharmaceutical Company Ltd, a privately-owned generics manufacturing company, based in Conghua City, Guangdong province, China.

AstraZeneca announced that it will reduce its US sales force by approximately 1,150 leadership positions and sales representatives as part of the company's ongoing strategy to operate its business more efficiently to best serve patients in the US.

Amgen (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

Pfizer Inc. (NYSE: PFE) has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

Bristol-Myers Squibb Company (NYSE:BMY) has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435,

Today a panel of experts in media, technology and healthcare are gathering to discuss the topic "New media - drivers of democratization and development?" at the 2011 Novartis Foundation for Sustainable Development (NFSD) symposium in Basel, Switzerland.